A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

M. A. Nauck,S Duran,Dennis Kim,Don Johns,Justin Northrup,Andreas Festa,R. Brodows,Michael Trautmann

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

2007

M. A. Nauck
S Duran
Dennis Kim
Don Johns
Justin Northrup
Andreas Festa
R. Brodows
Michael Trautmann

Aims/hypothesis The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart.

Keywords:

Metformin
Insulin
Sulfonylurea
Type 2 diabetes
Exenatide
Incretin
Diabetes mellitus
Endocrinology
Pancreatic hormone
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

425

Citations